Goodwin Procter·PHARMA / BIOTECH

Eli Lilly to Acquire Merida Biosciences for $2.875 Billion

Eli Lilly announces definitive agreement to acquire Merida Biosciences, a biotech with antibody-engineering platform targeting pathogenic autoantibodies in autoimmune diseases, in cash deal worth up to $2.875B expected to close Q4 2026.

eli-lilly-merida-acquisitionpharma-ma-dealbiotech-acquisitionantibody-platform-autoimmunegraves-disease-therapyhealthcare-ma-2026
Read the original firm alert → Saturday, September 5, 2026

Stay ahead

Join the digest.

One email when the daily AmLaw 100 briefing ships. No noise, no pitch decks — just the grade 4–5 signal.